AHA Dec. 22 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.

PhRMA and AstraZeneca challenged the state law as preempted by the federal law that created the 340B program, and AHA asserts that their challenge should be rejected.

鈥淧hRMA and AstraZeneca cannot demonstrate that Congress intended to create or occupy any field through its 340B legislation,鈥 the brief states. 鈥淣or does Louisiana law conflict with the federal 340B statute. In reality, it furthers Congress鈥 goal in enacting the 340B program: to enable hospitals to 鈥榮tretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.鈥欌

AHA was joined in filing the amicus brief by the Louisiana Hospital Association, the Rural Hospital Coalition and 340B Health.

Related News Articles

Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation鈥
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from鈥
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state鈥檚 law protecting 340B pricing for contract pharmacy arrangements. The鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model 鈥渨as within its statutory鈥
Headline
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold鈥